Chemo-immunotherapy before surgery for recurrent nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether giving chemotherapy plus immunotherapy (pembrolizumab) before and after surgery can help people whose nasopharyngeal cancer has come back in the same area (locally recurrent). The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have nasopharyngeal cancer that has come back in the same area (locally recurrent) and has not been treated for this recurrence yet
- Your cancer must test positive for the Epstein-Barr virus (EBV), either by a special stain or by a blood test
- You must be in good overall health (able to care for yourself) and free of major medical problems like autoimmune disease or other cancers
- You have not had prior immunotherapy (like PD-1 or PD-L1 inhibitors) or certain other cancer treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests whether a targeted radiation therapy, combined with the immunotherapy drug toripalimab before and after treatment, can reduce side effects while still effectively treating nasopharyngeal cancer. It is for patients with certain tumor sizes or stages who have not had prior neck radiation or immunotherapy.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.